Literature DB >> 8324870

Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

O van Tellingen1, J H Beijnen, W J Nooijen, A Bult.   

Abstract

We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its metabolites in plasma, tissue, faeces and urine specimens. Pharmacokinetics studies were performed in male FVB mice receiving VBL by intravenous (i.v.) bolus injection at a dose of 6 mg/kg. Plasma concentrations were monitored until 48 h after drug administration. Urine and faeces samples were collected in 24-h portions for up to 72 h and tissue samples were obtained at 4, 24, 72 and 168 h after drug administration. To facilitate a comparison between the findings we obtained by high-performance liquid chromatography (HPLC) and the results of previous studies using radiolabeled drug monitoring, some of the animals were also given radiolabeled drug. Large discrepancies were observed between the results obtained by the two methods. Excretion of the radiolabel in faeces and urine was 85% of the dose within 72 h. HPLC revealed that only 18% of the dose was excreted as unchanged drug and 19%, as measurable metabolites [O4-deacetylvinblastine (DVBL) and two unknown compounds]. In most of the tissues taken at 4 h after drug administration, virtually all of the radioactivity represented VBL or DVBL. In all tissues taken at 72 h after drug administration, however, only very little of the radioactivity remained in the form of these compounds. Following the administration, VBL and DVBL were distributed extensively to most tissues. Many tissues appeared to possess effective means of extruding the cytotoxic drug with decreasing plasma levels. However, in some organs, including those from the genital tract and lymphatic tissues, VBL and DVBL were retained for prolonged periods. Our studies confirm previous indications that selective retention may be the basis of the activity of VBL against malignant transformations derived from these tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324870     DOI: 10.1007/bf00686174

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

Review 1.  Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.

Authors:  O Van Tellingen; J H Beijnen; W J Nooyen
Journal:  J Pharm Biomed Anal       Date:  1991       Impact factor: 3.935

2.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

3.  Disposition and tissue levels of [3H]vindesine in rats.

Authors:  H W Culp; W D Daniels; R E McMahon
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

4.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

Authors:  X J Zhou; M Martin; M Placidi; J P Cano; R Rahmani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

5.  Distribution and excretion of (3H)vincristine in the rat and the dog.

Authors:  M C Castle; D A Margileth; V T Oliverio
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

6.  High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.

Authors:  O van Tellingen; J H Beijnen; R Baurain; W W ten Bokkel Huinink; H R van der Woude; W J Nooyen
Journal:  J Chromatogr       Date:  1991-08-16

7.  Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.

Authors:  J A Houghton; L G Williams; P M Torrance; P J Houghton
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Distribution and metabolism of vincristine in mice, rats, dogs, and monkeys.

Authors:  S M El Dareer; V M White; F P Chen; L B Mellet; D L Hill
Journal:  Cancer Treat Rep       Date:  1977-10

Review 9.  Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).

Authors:  O van Tellingen; J H Sips; J H Beijnen; A Bult; W J Nooijen
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

10.  The distribution of [3H]vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid.

Authors:  R L Noble; P W Gout; L L Wijcik; H F Hebden; C T Beer
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  3 in total

Review 1.  Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.

Authors:  O van Tellingen
Journal:  Pharm World Sci       Date:  1994-06-10

2.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; A L Sonneveldt; J H Beijnen; W J Nooijen; J J Kettenes-van den Bosch; C Versluis; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.